Leading with Clinical Science

at ACC.23/WCC

 

Cleerly is pleased to be part of the ACC.23/WCC conversation on the latest science and innovation, and practice changing updates that are advancing cardiovascular care. We will share new clinical evidence that champions the accuracy and effectiveness of using AI-enabled CCTA to guide personalized evaluation and treatment of coronary artery disease. Connect with us to learn how we are leading with clinical science and advanced precision heart disease detection technology to help address the world’s number one public health epidemic.

ACC.23/WCC Exhibit Hall

 

 

Connect with the Cleerly team at

Booth #1942

— or —
Schedule a meeting with our team in

ExpoSuite #2513

 

Schedule Now
ATA Blog - featured image

Treat Disease by Targeting Atherosclerosis

Quantification of coronary artery disease (CAD) burden and atherosclerotic plaque type has been shown to be the strongest determinant of future risk of major adverse cardiac events (MACE).1 Learn about new treatment algorithms, outlined by the Innovations in Prevention Working Group of the American College of Cardiology, that provide personalized recommendations for medical interventions based on the combination of coronary computed tomography angiography (CCTA) quantification of atherosclerotic plaque burden and traditional cardiovascular risk factors from existing clinical guidelines.

Read the Blog

 

Attend one of our ACC.23/WCC poster and oral abstract sessions:

Saturday, March 4
10:45 - 11:30 AM CT

Multimodality Imaging
Comparison of Coronary Plaque Characteristics in Younger South Asian and Non- Hispanic White Populations Utilizing CCTA: A Matched Cohort Study // More details ⇢

1:30 - 2:30 PM CT

Ischemic Heart Disease
Distribution of Coronary Atherosclerosis by Sex in Asymptomatic U.S Population Using Quantitative CT Plaque Analysis: Results From the Miami Heart Study // More details ⇢

2:15 - 2:25 PM CT

Innovation, Digital Health, and Technology
AI-QCT Demonstrates Superior Accuracy for the Diagnosis of Obstructive CAD by QCA Standard Compared to Core Lab CCTA Interpretation // More details ⇢

3:00 - 4:00 PM CT

Learning from Machines: Artificial Intelligence in Cardiovascular Imaging
High Diagnostic Accuracy of AI-Ischemia in Comparison to PET, FFR-CT, SPECT, and Invasive FFR: A PACIFIC Trial Sub-Study // More details ⇢

Sunday, March 5
9:30 - 9:40 AM CT

Imaging and Prevention
Firefighters Coronary Plaque Prevalence and Characteristics in Comparison to Non-Firefighters // More details ⇢

9:30 - 10:00 AM CT

Multimodality Imaging
Elevated Lp(a) and Inflammatory Markers Are Associated with Increased Low-Density Plaque Volume, Which May Explain Increased ASCVD Risk // More details ⇢

1:45 - 2:30 PM CT

Multimodality Imaging
Race/Ethnic Differences in Coronary Atherosclerotic Plaque Assessed on Cardiac Computed Tomography Angiography (CCTA) in an Asymptomatic United States Population: Results from the Miami Heart Study (MIHEART) // More details ⇢

Monday, March 6
9:45 - 11:45 AM CT

Predicting Risk and Preventing Events in Chronic CAD
Quantitative Plaque Staging System Predicts Long-Term Cardiovascular Outcomes in Patients At Risk for Atherosclerotic Cardiovascular Disease // More details ⇢

10:45 - 11:30 AM CT

Prevention and Health Promotion
Distribution of Coronary Atherosclerosis in Patients with Diabetes Mellitus, Using Quantitative CT Plaque Analysis: Results from the Miami Heart Study // More details ⇢

Connect with the Cleerly team at booth #1942 or schedule a meeting with us at ExpoSuite #2513 in the ACC.23/WCC exhibit hall.

Schedule Now

References:
1 Atherosclerosis. Nature Reviews Disease Primers. Aug. 16, 2019.

Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.